In a recent study, lenvatinib was shown to activate feedback signaling through EGFR-PAK2-ERK1/2 and EGFR-PAK2-ERK5 pathways in EGFR expressing HCC cell lines (40). The gene discussed is PAK2; the disease is hepatocellular carcinoma.